主页 > 医学文档 >
【文摘发布】吉非罗齐治疗严重鼠流感
Title: Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza.
Author: Budd A, Alleva L, Alsharifi M, et al
Abstact: Gemfibrozil, an agent that inhibits production of pro-inflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (n=50) to 52% in mice administered 60 mg/kg/day gemfibrozil (n=46) (p=0.0026). If this principle translates across to patients, a drug already approved for human use, albeit by a different route for another purpose, might be relatively fast to adapt for use against influenza disease, conceivably including human infection by a derivative of the avian H5N1 strain.
PMID: 17562808 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-01 17:11
医学,生命科学网